vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and UNITY BANCORP INC (UNTY). Click either name above to swap in a different company.
UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $18.7M, roughly 1.9× CytomX Therapeutics, Inc.). UNITY BANCORP INC runs the higher net margin — 43.9% vs -0.8%, a 44.7% gap on every dollar of revenue. On growth, UNITY BANCORP INC posted the faster year-over-year revenue change (24.2% vs -25.7%). UNITY BANCORP INC produced more free cash flow last quarter ($44.3M vs $-15.8M). Over the past eight quarters, UNITY BANCORP INC's revenue compounded faster (17.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.
CTMX vs UNTY — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $35.3M |
| Net Profit | $-154.0K | $15.5M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 55.8% |
| Net Margin | -0.8% | 43.9% |
| Revenue YoY | -25.7% | 24.2% |
| Net Profit YoY | 97.6% | 34.5% |
| EPS (diluted) | — | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $35.3M | ||
| Q3 25 | — | $32.8M | ||
| Q2 25 | $18.7M | $34.4M | ||
| Q1 25 | $50.9M | $29.4M | ||
| Q4 24 | $38.1M | $28.4M | ||
| Q3 24 | $33.4M | $27.7M | ||
| Q2 24 | $25.1M | $25.5M | ||
| Q1 24 | $41.5M | $25.6M |
| Q4 25 | — | $15.5M | ||
| Q3 25 | — | $14.4M | ||
| Q2 25 | $-154.0K | $16.5M | ||
| Q1 25 | $23.5M | $11.6M | ||
| Q4 24 | $18.9M | $11.5M | ||
| Q3 24 | $5.7M | $10.9M | ||
| Q2 24 | $-6.5M | $9.5M | ||
| Q1 24 | $13.8M | $9.6M |
| Q4 25 | — | 55.8% | ||
| Q3 25 | — | 57.5% | ||
| Q2 25 | -6.9% | 62.6% | ||
| Q1 25 | 44.4% | 52.6% | ||
| Q4 24 | 46.4% | 51.0% | ||
| Q3 24 | 12.3% | 52.7% | ||
| Q2 24 | -33.7% | 49.3% | ||
| Q1 24 | 28.1% | 50.0% |
| Q4 25 | — | 43.9% | ||
| Q3 25 | — | 43.8% | ||
| Q2 25 | -0.8% | 48.0% | ||
| Q1 25 | 46.2% | 39.5% | ||
| Q4 24 | 49.6% | 40.5% | ||
| Q3 24 | 17.2% | 39.4% | ||
| Q2 24 | -26.0% | 37.1% | ||
| Q1 24 | 33.3% | 37.5% |
| Q4 25 | — | $1.52 | ||
| Q3 25 | — | $1.41 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.13 | ||
| Q4 24 | — | $1.13 | ||
| Q3 24 | — | $1.07 | ||
| Q2 24 | — | $0.92 | ||
| Q1 24 | — | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $345.6M |
| Total Assets | $175.1M | $3.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $230.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $345.6M | ||
| Q3 25 | — | $334.0M | ||
| Q2 25 | $119.9M | $319.8M | ||
| Q1 25 | $25.0M | $306.1M | ||
| Q4 24 | $-456.0K | $295.6M | ||
| Q3 24 | $-23.5M | $284.3M | ||
| Q2 24 | $-31.2M | $273.4M | ||
| Q1 24 | $-31.7M | $266.8M |
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | $175.1M | $2.9B | ||
| Q1 25 | $98.5M | $2.8B | ||
| Q4 24 | $120.5M | $2.7B | ||
| Q3 24 | $139.0M | $2.6B | ||
| Q2 24 | $159.2M | $2.6B | ||
| Q1 24 | $184.7M | $2.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $44.9M |
| Free Cash FlowOCF − Capex | $-15.8M | $44.3M |
| FCF MarginFCF / Revenue | -84.6% | 125.7% |
| Capex IntensityCapex / Revenue | 0.1% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 2.90× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $81.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $44.9M | ||
| Q3 25 | — | $45.5M | ||
| Q2 25 | $-15.8M | $-25.3M | ||
| Q1 25 | $-21.0M | $17.9M | ||
| Q4 24 | $-19.9M | $48.0M | ||
| Q3 24 | $-20.7M | $17.7M | ||
| Q2 24 | $-19.5M | $-8.4M | ||
| Q1 24 | $-26.0M | $15.8M |
| Q4 25 | — | $44.3M | ||
| Q3 25 | — | $45.3M | ||
| Q2 25 | $-15.8M | $-25.5M | ||
| Q1 25 | $-21.2M | $17.6M | ||
| Q4 24 | $-20.0M | $47.3M | ||
| Q3 24 | $-20.7M | $17.5M | ||
| Q2 24 | $-19.6M | $-8.6M | ||
| Q1 24 | $-26.2M | $15.7M |
| Q4 25 | — | 125.7% | ||
| Q3 25 | — | 138.1% | ||
| Q2 25 | -84.6% | -74.2% | ||
| Q1 25 | -41.6% | 59.9% | ||
| Q4 24 | -52.5% | 166.5% | ||
| Q3 24 | -62.1% | 63.3% | ||
| Q2 24 | -78.2% | -33.7% | ||
| Q1 24 | -63.1% | 61.4% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.2% | 1.0% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | — | 2.90× | ||
| Q3 25 | — | 3.16× | ||
| Q2 25 | — | -1.54× | ||
| Q1 25 | -0.89× | 1.54× | ||
| Q4 24 | -1.05× | 4.17× | ||
| Q3 24 | -3.61× | 1.62× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | -1.89× | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
UNTY
Segment breakdown not available.
